5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA

Neurobiology of Aging

Volumn 33, Issue 1, 2012, Pages 194.e5-194.e15

  Huot, Philippe ^a,b   Johnston, Tom H ^a   Winkelmolen, Lieke ^a   Fox, Susan H ^a,b   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Autoradiography; Dyskinesia; Macaque; MPTP; Parkinson's disease; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; DOPAMINE; KETANSERIN; RADIOLIGAND; SEROTONIN 2A RECEPTOR; LEVODOPA; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DYSKINESIA; FEMALE; LIGAND BINDING; LONG TERM CARE; MACACA; MOTOR CORTEX; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; SINGLE DRUG DOSE; ANIMAL; BRAIN; INTOXICATION; MACACA FASCICULARIS; METABOLISM; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; AUTORADIOGRAPHY; BRAIN; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MPTP POISONING; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SYNAPTIC TRANSMISSION;

EID: 81355142874     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.04.035     Document Type: Article

References (69)

1. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997, 36:589-599.
2. Arai R., Karasawa N., Geffard M., Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett 1995, 195:195-198.
3. Bedard P.J., Di Paolo T., Falardeau P., Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H] spiperone binding. Brain Res 1986, 379:294-299.
4. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci 2001, 2:577-588.
5. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci 2001, 21:6853-6861.
6. Bezard E., Imbert C., Deloire X., Bioulac B., Gross C.E. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 1997, 766:107-112.
7. Bhattacharyya S., Raote I., Bhattacharya A., Miledi R., Panicker M.M. Activation, internalization, and recycling of the serotonin 2A receptor by dopamine. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15248-15253.
8. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol 1994, 17:73-82.
9. Boulet S., Mounayar S., Poupard A., Bertrand A., Jan C., Pessiglione M., Hirsch E.C., Feuerstein C., Francois C., Feger J., Savasta M., Tremblay L. Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J. Neurosci 2008, 28:9575-9584.
10. Bubser M., Backstrom J.R., Sanders-Bush E., Roth B.L., Deutch A.Y. Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum. Synapse 2001, 39:297-304.
11. Calabresi P., Di Filippo M., Ghiglieri V., Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov. Disord 2008, 23(suppl 3):S570-S579.
12. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
13. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res 2008, 172:465-478.
14. Cenci M.A. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat. Disord 2007, 13(suppl 3):S263-S267.
15. Chen C.P., Alder J.T., Bray L., Kingsbury A.E., Francis P.T., Foster O.J. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann. N.Y. Acad. Sci 1998, 861:288-289.
16. Darchen F., Scherman D., Laduron P.M., Henry J.P. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol. Pharmacol 1988, 33:672-677.
17. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res 2007, 179:76-89.
18. Dupre K.B., Eskow K.L., Barnum C.J., Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
19. Durif F., Debilly B., Galitzky M., Morand D., Viallet F., Borg M., Thobois S., Broussolle E., Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004, 62:381-388.
20. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. Neurol. Sci 1971, 14:427-455.
21. Fox S.H., Chuang R., Brotchie J.M. Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog. Brain Res 2008, 172:479-494.
22. Fox S.H., Chuang R., Brotchie J.M. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov. Disord 2009, 24:1255-1266.
23. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord 2007, 22:179-186.
24. Gomez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol 1993, 16:418-427.
25. Gregoire L., Samadi P., Graham J., Bedard P.J., Bartoszyk G.D., Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat. Disord 2009, 15:445-452.
26. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., Standaert D.G. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48:503-516.
27. Hely M.A., Morris J.G., Reid W.G., Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord 2005, 20:190-199.
28. Huot P., Levesque M., Morissette M., Calon F., Dridi M., Di Paolo T., Parent A. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. J. Chem. Neuroanat 2008, 35:77-84.
29. Jackson M.J., Al-Barghouthy G., Pearce R.K., Smith L., Hagan J.J., Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol. Biochem. Behav 2004, 79:391-400.
30. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci 2008, 9:665-677.
31. Johnston T.H., Fox S.H., McIldowie M.J., Piggott M.J., Brotchie J.M. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther 2010, 333:865-873.
32. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., Matsunaga M. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease [in Japanese]. No Shinkei 2002, 54:133-137.
33. Katzenschlager R., Manson A.J., Evans A., Watt H., Lees A.J. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J. Neurol. Neurosurg. Psychiatry 2004, 75:295-297.
34. Leysen J.E., Awouters F., Kennis L., Laduron P.M., Vandenberk J., Janssen P.A. Receptor binding profile of R41 four hundred and sixty-eight, a novel antagonist at five-HT2 receptors. Life Sci 1981, 28:1015-1022.
35. Leysen J.E., Niemegeers C.J., Van Nueten J.M., Laduron P.M. [3H] Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol 1982, 21:301-314.
36. Lopez-Gimenez J.F., Vilaro M.T., Palacios J.M., Mengod G. Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H] MDL100,nine hundred and seven autoradiography and in situ hybridization studies. J. Comp. Neurol 2001, 429:571-589.
37. Lucas G., Spampinato U. Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J. Neurochem 2000, 74:693-701.
38. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci 2002, 15:120-132.
39. Marsden C.D. The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 1982, 32:514-539.
40. Martin R.F., Bowden D.M. A stereotaxic template atlas of the macaque brain for digital imaging and quantitative neuroanatomy. Neuroimage 1996, 4:119-150.
41. Mela F., Marti M., Dekundy A., Danysz W., Morari M., Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem 2007, 101:483-497.
42. Mijnster M.J., Raimundo A.G., Koskuba K., Klop H., Docter G.J., Groenewegen H.J., Voorn P. Regional and cellular distribution of serotonin 5-hydroxytryptamine2a receptor mRNA in the nucleus accumbens, olfactory tubercle, and caudate putamen of the rat. J. Comp. Neurol 1997, 389:1-11.
43. Miller J.A., Zahniser N.R. The use of 14C-labeled tissue paste standards for the calibration of 125I-labeled ligands in quantitative autoradiography. Neurosci. Lett 1987, 81:345-350.
44. Morin N., Gregoire L., Gomez-Mancilla B., Gasparini F., Di Paolo T. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010, 58:981-986.
45. Neuman R.S., Rahman S. Ca2+ mobilizing agents mimic serotonin five-HT2A facilitation of N-methyl-D-aspartate depolarization. Behav. Brain Res 1996, 73:273-275.
46. Oh J.D., Bibbiani F., Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol 2002, 177:557-564.
47. Oquendo M.A., Russo S.A., Underwood M.D., Kassir S.A., Ellis S.P., Mann J.J., Arango V. Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide. Biol. Psychiatry 2006, 59:235-243.
48. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev 1995, 20:91-127.
49. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch. Neurol 2009, 66:563-570. Parkinson Study Group.
50. Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-two receptors. Brain Res 1985, 346:231-249.
51. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain - IV. Autoradiographic mapping of serotonin-two receptors. Neuroscience 1987, 21:123-139.
52. Pearce R.K., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-four-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord 1995, 10:731-740.
53. Pehek E.A., Nocjar C., Roth B.L., Byrd T.A., Mabrouk O.S. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 2006, 31:265-277.
54. Perez-Otano I., Herrero M.T., Oset C., De Ceballos M.L., Luquin M.R., Obeso J.A., Del Rio J. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res 1991, 567:127-132.
55. Pifl C., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991, 44:591-605.
56. Rahman S., Neuman R.S. Activation of 5-HT2 receptors facilitates depolarization of neocortical neurons by N-methyl-D-aspartate. Eur. J. Pharmacol 1993, 231:347-354.
57. Roberts C. ACP-one hundred and three, a 5-HT2A receptor inverse agonist. Curr. Opin. Investig. Drugs 2006, 7:653-660.
58. Samadi P., Gregoire L., Morissette M., Calon F., Hadj Tahar A., Dridi M., Belanger N., Meltzer L.T., Bedard P.J., Di Paolo T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging 2008, 29:1040-1051.
59. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983, 275:321-328.
60. Schmidt C.J., Sullivan C.K., Fadayel G.M. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem 1994, 62:1382-1389.
61. Smith L.A., Jackson M.J., Hansard M.J., Maratos E., Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov. Disord 2003, 18:487-495.
62. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
63. Vanover K.E., Betz A.J., Weber S.M., Bibbiani F., Kielaite A., Weiner D.M., Davis R.E., Chase T.N., Salamone J.D. A 5-HT2A receptor inverse agonist, ACP-one hundred and three, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav 2008, 90:540-544.
64. Visanji N.P., Fox S.H., Johnston T.H., Millan M.J., Brotchie J.M. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J. Pharmacol. Exp. Ther 2009, 328:276-283.
65. Visanji N.P., Gomez-Ramirez J., Johnston T.H., Pires D., Voon V., Brotchie J.M., Fox S.H. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord 2006, 21:1879-1891.
66. Willins D.L., Deutch A.Y., Roth B.L. Serotonin five-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 1997, 27:79-82.
67. Zgombick J.M., Bard J.A., Kucharewicz S.A., Urquhart D.A., Weinshank R.L., Branchek T.A. Molecular cloning and pharmacological characterization of guinea pig 5-HT1B and 5-HT1D receptors. Neuropharmacology 1997, 36:513-524.
68. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2163-2168.
69. Zhang X., Andren P.E., Svenningsson P. Changes on five-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol. Behav 2007, 92:29-33.